-+ 0.00%
-+ 0.00%
-+ 0.00%
Fate Therapeutics wins $15 million CIRM grant for FT819 lupus nephritis Phase 2 trial
Share
Listen to the news
Fate Therapeutics wins $15 million CIRM grant for FT819 lupus nephritis Phase 2 trial
  • Fate Therapeutics won a USD 15 million CLIN2 grant from the California Institute for Regenerative Medicine to advance its RECLAIM-LN trial.
  • Funding supports Phase 2, potentially registrational testing of FT819 off-the-shelf CAR T-cell therapy in refractory lupus nephritis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609250700PRIMZONEFULLFEED9833804) on September 25, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending